Holen Sie sich die Stockscreener-App
2.13
7.39%
-0.17
Schlusskurs vom Vortag:
$2.30
Offen:
$2.27
24-Stunden-Volumen:
122.71K
Relative Volume:
0.07
Marktkapitalisierung:
$6.61M
Einnahmen:
$1.38M
Nettoeinkommen (Verlust:
$-179.05M
KGV:
-0.3469
EPS:
-6.14
Netto-Cashflow:
$-155.03M
1W Leistung:
-7.79%
1M Leistung:
+494.97%
6M Leistung:
+213.01%
1J Leistung:
-32.38%
1-Tages-Spanne:
$2.10
$2.30
1-Wochen-Bereich:
$2.10
$2.60
52-Wochen-Spanne:
$0.16
$3.50
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Firmenname
Bioxcel Therapeutics Inc
Sektor
Branche
Telefon
203-643-8060
Adresse
555 LONG WHARF DRIVE, NEW HAVEN, CT
Vergleichen Sie BTAI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
2.13 | 6.61M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-21 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2023-07-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-03-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-01 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-06 | Bestätigt | BofA Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-02-01 | Eingeleitet | UBS | Buy |
| 2020-10-30 | Eingeleitet | Goldman | Buy |
| 2020-09-02 | Eingeleitet | Jefferies | Buy |
| 2020-08-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-04 | Eingeleitet | Guggenheim | Buy |
| 2020-04-01 | Eingeleitet | BofA/Merrill | Buy |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
Alle ansehen
Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten
BTAI stock plunges to 52-week low of $2.16 amid market challenges - Investing.com Nigeria
BioXcel Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
BioXcel Therapeutics expands board, appoints new director - MSN
BioXcel Therapeutics announces 1-for-16 reverse stock split - MSN
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Update - MarketBeat
BTAI stock touches 52-week low at $2.53 amid sharp annual decline - MSN
A significant driver of top-line growth: BioXcel Therapeutics Inc (BTAI) - SETE News
You Should Look At The Stock Forecast For BioXcel Therapeutics Inc (NASDAQ: BTAI). - Marketing Sentinel
BioXcel Therapeutics Inc (BTAI) Shares Down Despite Recent Market Volatility - The News Heater
The Psychology of BioXcel Therapeutics Inc Inc. (BTAI) Price Performance: Understanding Market Sentiment - The InvestChronicle
Balance Sheet Insights: BioXcel Therapeutics Inc (BTAI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential - Marketscreener.com
BioXcel Therapeutics, Inc. Appoints June Bray to its Board of Directors -March 01, 2021 at 10:13 am EST - Marketscreener.com
BioXcel Therapeutics Announces Appointment of Reina Benabou, M.D., Ph.D., as Senior Vice President and Chief Development Officer - Marketscreener.com
BioXcel Therapeutics Shares Rise Premarket on FDA Fast-Track Designation -February 12, 2024 at 07:43 am EST - Marketscreener.com
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts BioXcel Therapeutics (BTAI) Investors to Pending Securities Fraud Class Action, Encourages Investors with Substantial Losses to Contact Firm’s Attorneys - ACCESS Newswire
BioXcel Therapeutics enacts 1-for-16 reverse stock split - MSN
BioXcel Therapeutics announces reverse stock split - Hartford Business Journal
BioXcel Therapeutics announces 1-for-16 reverse stock split By Investing.com - Investing.com Nigeria
BioXcel to execute 1-for-16 reverse stock split - MSN
BioXcel to Implement Reverse Stock Split; Shares Fall -February 06, 2025 at 01:28 pm EST - Marketscreener.com
BioXcel Therapeutics Announces Reverse Stock Split - citybiz
BioXcel Therapeutics enacts 1-for-16 reverse stock split By Investing.com - Investing.com Canada
BioXcel Therapeutics Sets 1-for-16 Reverse Stock Split To Regain Nasdaq Listing - Nasdaq
BioXcel's Strategic Reverse Split: Critical Move to Preserve Nasdaq StatusWhat's at Stake - StockTitan
BioXcel Therapeutics advances key clinical trials - Investing.com India
BioXcel Therapeutics Inc (BTAI) Shares Plummet Below 1-Year High - The News Heater
BioXcel Therapeutics advances key clinical trials By Investing.com - Investing.com South Africa
BioXcel Therapeutics Provides Clinical and Business Update -February 05, 2025 at 07:45 am EST - Marketscreener.com
BioXcel Therapeutics Provides Clinical and Business Update - The Manila Times
Clinical Progress Alert: BioXcel's Strategic Moves in Agitation Treatment Trials Gain Momentum - StockTitan
BioXcel Therapeutics, Inc. Provides Clinical and Business Update -February 05, 2025 at 07:00 am EST - Marketscreener.com
Observations on the BioXcel Therapeutics Inc (NASDAQ:BTAI) Growth Curve - US Post News
What is HC Wainwright’s Forecast for BTAI FY2024 Earnings? - Defense World
BioXcel Therapeutics Holds Special Meeting, Approves Reverse Stock Split Plan - Defense World
HC Wainwright Cuts BioXcel Therapeutics (NASDAQ:BTAI) Price Target to $3.00 - Defense World
BioXcel Therapeutics stock hits 52-week low at $0.3 - MSN
BioXcel Therapeutics stock hits 52-week low at $0.3 By Investing.com - Investing.com Australia
Finanzdaten der Bioxcel Therapeutics Inc-Aktie (BTAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bioxcel Therapeutics Inc-Aktie (BTAI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mehta Vimal | CEO and President |
Dec 16 '24 |
Sale |
0.36 |
3,117 |
1,131 |
59,605 |
| Steinhart Richard I | Chief Financial Officer |
Dec 16 '24 |
Sale |
0.36 |
577 |
207 |
20,932 |
| Rodriguez Javier | See Remarks |
Dec 16 '24 |
Sale |
0.36 |
430 |
153 |
24,423 |
| Yocca Frank | Chief Scientific Officer |
Dec 16 '24 |
Sale |
0.35 |
430 |
152 |
28,931 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):